Introducti on: Polyarthriti s is a common presentati on of pati ents att ending medicine outpati ent department. Among various causes Rheumatoid arthriti s is the commonest and a well established case has disti nct characteristi c features. However the early presentati on of this disease has not been clear thus leading to delay in treatment. The objecti ves of this study was to identi fy the various causes of polyarthriti s in our clinical practi ce, discuss the varied clinical presentati on of rheumatoid arthriti s including early Rheumatoid arthriti s and to evaluate the treatment response during one year follow up.
INTRODUCTION
Joint Pain is one of the common complaints of pati ents visiti ng a clinician. Apart from nonspecifi c arthralgia, a signifi cant number of pati ents present with infl ammatory arthriti s. Infl ammatory arthriti s is a conditi on characterized by pain and swelling in the joints associated with limitati on of movements. The most common cause of chronic infl ammatory arthriti s is rheumatoid arthriti s (RA) with a worldwide prevalence of 0.5% -1% of adult populati on¹. Typically beginning in multi ple small joints of the hands and feet in a symmetric fashion, RA has many variati ons, including months or years of recurrent monoarthriti s (palindromic rheumati sm)² before a typical patt ern evolves. Disease durati on of 12 weeks or more is strongly predicti ve of persistent RA 3. The symmetry of RA is someti mes overemphasized, and it must be appreciated that this is a general, rough symmetry. RA can have unilateral manifestati on 4, 5 and early RA may have varied presentati ons not abiding with the American College of Rheumatology (ARA) criteria or the American College of Rhematological Diseases (ACR, 1988) criteria 6 . Though RA is the most common cause of polyarthriti s, many other causes are also encountered ti me and again. While some of the arthriti s like Ankylosing spondyliti s is diffi cult to treat and also very diffi cult to prevent from progressing, others like arthriti s due to rheumati c fever, gout can be prevented and treated 7, 8 . In this context tuberculosis is worth menti oning in Asian populati on. It can present with symmetrical polyarthriti s known as Poncets disease 9, 10 . It responds to anti tubercular therapy and heals without residual disease. Rheumatoid arthriti s can also be remarkably controlled with disease modifying drugs, if detected early and treated before joint damage has occurred 11, 12 . Even though arthriti s is common, study in this fi eld is lacking in our country. Only recently have few specialist trained in rheumatology, started rheumatologic practi ce in Nepal. We do not have practi ce guide lines and management protocol as our cohorts of pati ents have not been studied. Hence a need for prospecti ve study of this group of pati ent was needed.
The aim of this study was to diagnose various types of arthriti s encountered in our populati on and to evaluate the various clinical presentati ons of rheumatoid arthriti s. Early rheumatoid arthriti s that does not exactly fi t into the ACR 13, 14 criteria is largely missed and treated as nonspecifi c arthriti s. We also want to evaluate the clinical presentati on of this group of pati ents and highlight the early presentati on. Similarly as the onset and progress of joint deformity and destructi on in RA is directly related with early diagnosis and therapy this study also tries to assess the response of anti -rheumatoid drugs in our pati ents with use of locally available drugs.
METHOD
All pati ents presenti ng to the medical outpati ent department of a medical college hospital with history of joint pain and swelling of more than two joints, for more than two weeks durati on, were prospecti vely enrolled in the study period of April 2008 to April 2010. A detailed history was taken and examinati on done by a single experienced clinician. Pati ent characteristi cs included were mode of onset, durati on of joint pain, morning sti ff ness, number of joints and joint areas involved, involvement of small joints of the hands and feet, presence or absence of axial joint involvement and sacroiliti s, presence of tenderness, swelling and synoviti s.
All were assessed for presence of nodules, rash and extraarti cular features including all system. For laboratory investi gati on complete blood count and ESR, and specifi c investi gati ons were sent if needed on the fi rst day and data entered on day eight aft er reports were collected. All pati ents with clinical diagnosis of rheumatoid arthriti s were diagnosed as per The American Rheumati sm Associati on 1987 revised criteria for the classifi cati on of rheumatoid arthriti s 4, 12 and those with early incomplete criteria were diagnosed with presence of seropositi vity. Seropositi vity defi ned as presence of RA factor (IgM) 13, 14, 15, 16, 17 >60 units and or A-CCP 18,19, (anti citrullinated cyclic pepti de anti body), ti ter>15 units done by Elisa assay in a standard laboratory. Ankylosing Spondyliti s and seronegati ve spondyloarthriti s was diagnosed on the basis of presence of sacroiliti s, butt ock pain and nocturnal awakening with back pain, morning sti ff ness more than 30 minutes and family history 20 . Diagnosis of tuberculosis was considered if arthriti s was present along with evening rise of temperature and showed positi ve mantoux test of > 20 mm with or without presence of erythema nodosum and phlyctenular conjuncti viti s 9, 10 . Rheumati c fever was diagnosed by Jones criteria 21 . Arthriti s with features of connecti ve ti ssue diseases other than RA were grouped as other connecti ve ti ssue diseases. Gouty arthriti s and non specifi c reacti ve arthriti s were grouped as ''others". All the pati ents with newly diagnosed rheumatoid arthriti s were evaluated by DAS 28 ESR 22, 23, 24, 25, 26, 27, 28 score aft er six weeks of persistent arthriti s 13 and started on methotrexate at loading dose of 15mg/week 28, 29 . Those who had long durati on of disease and had DAS 28 >5.1 at presentati on were started on more than two DMARD including hydroxychloroquine 400 mg and sulfasalazine 1gm 30, 31 . Follow up evaluati on was done at 6 weeks, three months, six months and one year. All were instructed to visit in between if any drug complicati ons arose or break through pain occurred. Treatment response in rheumatoid arthriti s was defi ned as the improvement in DAS 28 score by > 1.2 from baseline score 23 . The dose of methotrexate was tapered if possible to lowest 7.5-10mg/week if sustained response was seen, aft er six months. The scoring was done at three, six and 12 months but comparison was done between the third and the 12 months score. They were allowed to have NSAID as needed but frequency restricted to 1-3 ti mes per week and if frequency was more than that, was asked to report when short course steroid was initi ated. Maximum dose of methotrexate was 20mg/week, Hydroxychloroquin was 400mg/day with Salphasalazine at 2gm per day. Pati ents having DAS score > 6.1 at the onset were allowed to have steroids 30, 31 for 7-10 days in a tapering dose. Steroid injecti ons were allowed for few swollen joints at the ti me of follow up. All the data were entered in to the data sheet of SPSS version 17 and data analysis for relevant variables were done using descripti ve stati sti cs and t-test as required.
RESULTS
A total of 54 pati ents presenti ng with infl ammatory polyarthriti s were enrolled. Rheumatoid arthriti s was the most common arthriti s and consti tuted 77.8% (n=42) with a period prevalence of 0.7% and was followed by seronegati ve spondyloarthriti s (Fig.1) .
Tuberculosis presenti ng as polyarthriti s was consistently associated with fever, erythema nodosum and positi ve ulcerati ve mantoux test with reading >20mm. Mean age of the pati ents in RA group was 51.95±2.9 and non RA group was 31.92±6.13 (Fig 2) . There were 32 females and 22 males in the study group. Female and male rati o in the rheumatoid group was 1.8:1 and 1.4:1 in non RA group. Clinical presentati on and comparison between the RA and Non RA group is shown in Table1. Morning sti ff ness > 45mins, involvement of more than two joint areas, boggy synovial swelling of the joints and joint deformiti es were signifi cantly present in the RA group (p>.05). Rheumatoid nodules were present in only 11.9% (n=5) of RA pati ents.
Pati ents presenti ng with early rheumatoid arthriti s had varied clinical presentati on (Table. 2) which manifested within a mean durati on of two months to two years before diagnosis. Interesti ngly 43% (n=18) of the pati ents had swelling and tenderness in overused joints almost 1.5 years prior to full clinical manifestati on. Flitti ng or migratory joint pain not considered to be a feature of rheumatoid arthriti s was also present in 14.3% (n=6) pati ents with mean durati on of 1.5 years prior to full blown presentati on.
In the rheumatoid group the MCPJ (metacarpophalyngeal joints) and PIP (proximal interphalyngeal joints) were involved in 90%, followed by wrist 80%, elbow 60% knee 60% (Table. 3). Para-arti cular site soft ti ssue involvement manifested as repeated chest pain, upper back pain, throat and anterior neck pain someti mes confused as thyroiditi s and pharyngiti s. Extraarti cular manifestati ons in our cohorts of RA cases were not signifi cant. One pati ents had pericarditi s and pericardial eff usion. 9.5% (n=4) had sicca syndrome with severe dryness of eye proved by Schirmers tear test. Two pati ents had fi ne inspiratory crepts at ling bases without clinical symptoms and only mild evidence of restricti ve lung disease in spirometry test. All these had disease durati on of more than fi ve years.
Regarding treatment Methotrexate as a DMARD was very eff ecti ve and tolerated in our cohort of RA. None of the pati ents had to be disconti nued due to side eff ects. Mean DAS 28 score on the second follow up was signifi cantly lower (p=<.05) compared with the DAS 28 score on the fi rst follow up (Table. 4) similarly pati ents on one DMARD ( methotrexate) had disease control comparable to more than two DMARD and increasing the number of DMARD did not show stati sti cally signifi cant disease control (p=0.95). 2.6±o.45
DISCUSSION
Rheumatoid arthriti s was the most common causes of infl ammatory arthriti s in our populati on. In our study the in hospital period prevalence was 0 .7% which is comparable to the prevalence in other studies. Females were more aff ected than male but the rati o was less than quoted in other studies 16, 17 . Among other causes of infl ammatory arthriti s, Spondyloti c arthriti s was the second most common as in other studies 18, 19 . Primary tuberculosis also presented as polyarthriti s and was associated with boggy synovial swelling of multi ple joints, mainly involving the wrist and ankle and was seen in young females. The presentati on was typical of Poncet's reacti ve arthriti s 20, 21 .
Regarding clinical features in rheumatoid arthriti s (Table. 2), those presenti ng within one year of onset of joint pain had characteristi c features. Signifi cant number of pati ents presented with unilateral symptoms and had morning sti ff ness less than 30 mins. Some of the pati ents presented with chondral site pain like anterior neck pain with tenderness over the hyoid bone and cricoids carti lage and diffi culty in swallowing. Temporomandibular arthriti s 32 was the symptoms that had a prolonged onset with a mean durati on of 1.9 years before full blown presentati on. Low back pain was also present in some pati ents diagnosed as RA.
Joint involvement in RA was almost similar to other studies with the MCP and PIP involved in maximum number of pati ents (Table 3) . However systemic and extra-arti cular manifestati on was negligible in our cohort of pati ents with RA. Interesti ngly aft er one year follow up, two of our pati ents died. One male RA pati ent died due to pericardial tamponade and a female with coexistent COAD died due to bronchogenic carcinoma which manifested almost 6 months aft er the pati ents initi ati on on methotrexate, compelling us to diagnose RA presenti ng as a paraneoplasti c syndrome 33 .
Regarding treatment our group of pati ents responded very well to Methotrexate 29, 30 and there was not much diff erence between the one DMARD and more than one DMARD group 33, 34 (Table.4 ). Apart from intermitt ent diarrhea and oral ulcers none of the pati ents reported much adverse eff ect. Those pati ents responding to methotrexate did fi ne with good treatment response at a dose ranging from10mg/week to 15mg/week. Those not showing response and requiring repeated NSAID and short course steroid (7-10 days) for more than three ti mes in six months period did not improve signifi cantly (p=.95) with three DMARD.
Due to practi cal problem we did not use radiological score to evaluate the response which may be the major drawback of our study. Treatment response was assessed using DAS28 ESR score and the mean diff erence in the score aft er treatment was signifi cantly bett er (Table.5 ). As the treatment response in the group with more than one DMARD were not stati sti cally diff erent and they had to be put on intermitt ent steroid we want to infer that these pati ents may be the ones to improve on biological agents 35 . But due to fi nancial constraints and lack of fund we could not add biological agents to these pati ents and had to be sati sfi ed with intermitt ent steroid and multi ple DMARD though our study shows that they could have been managed on only methotrexate with intermitt ent steroid.
CONCLUSION
We conclude that RA is a very common disabling arthriti s in our populati on, but reacti ve arthriti s like tubercular arthriti s may also present as polyarthriti s similar to rheumatoid arthriti s. Early presentati on of RA may not fi t in the typical ARA clinical criteria. Early diagnosis and treatment is essenti al to prevent joint damage. At this early stage serology may be helpful for diagnosis apart from the various presentati ons menti oned. Methotrexate is a very good drug for our populati on and adverse eff ect is not much. Since disease control is the goal of therapy intermitt ent steroid is very helpful. Pati ents not responding to multi ple DMARD should be considered candidates for the biological agents along with methotrexate.
